The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move

This episode of The BioPharm Brief covers three key developments shaping today’s biopharmaceutical landscape, with a focus on cell and gene therapy manufacturing, oncology drug development, and biosimilars market strategy. Experts highlight how early process design and CMC planning are critical to the success of advanced therapies, helping companies avoid costly delays and scale-up challenges. In clinical news, leronlimab demonstrates early clinical and biomarker activity in metastatic colorectal cancer, signaling potential progress in immunotherapy approaches for hard-to-treat cancers. Meanwhile, Amneal Pharmaceuticals’ acquisition of Kashiv BioSciences reflects a growing industry trend toward vertical integration in biosimilars development, manufacturing, and commercialization. Together, these stories underscore how aligning scientific innovation with scalable manufacturing and strategic investment is essential for success in modern biopharma.